Legend: 
= Applied Session,
= Theme Session,
= Presenter, Sheraton Seattle Hotel & Towers = “S”
Washington State Convention & Trade Center = “CC”, Grand Hyatt Seattle = “H”
|
|
|
|
|
424
|
Wed, 8/9/06, 10:30 AM - 12:20 PM
|
CC-620
|
|
Missing Data - Contributed - Papers
|
Biopharmaceutical Section, Biometrics Section
|
|
Chair(s): Soomin Park, Eli Lilly and Company
|
|
10:35 AM
|
Statistical Methods To Analyze Incomplete Clinical Trial Data —  Ohidul Siddiqui, U.S. Food and Drug Administration
|
|
10:50 AM
|
Mixed Model: an Alternative to LOCF as Primary Analysis — Cunshan Wang, Pfizer Inc.; Naitee Ting, Pfizer Inc.; Greg C. G. Wei, Pfizer Inc.
|
|
11:05 AM
|
Estimating Treatment Effect in Clinical Trials with Disease-Dependant Noncompliance — Kuenhi Tsai, Vertex Pharmaceuticals Incorporated; Peter Westfall, Texas Tech University; Stephan Ogenstad, Vertex Pharmaceuticals Incorporated; Miles Dunn, Vertex Pharmaceuticals Incorporated
|
|
11:20 AM
|
Variability in Visit Times in Clinical Trials and the Implications for a Common Mixed Model for Repeated Measures — Tristan Massie, U.S. Food and Drug Administration
|
|
11:35 AM
|
Using Stochastic Differential Equations for Imputation of Missing Values in Longitudinal Clinical Data — Naum Khutoryansky, Novo Nordisk
|
|
11:50 AM
|
What Is a Suitable Definition of Study Information in Longitudinal Clinical Trials? — Guoguang Ma, Merck & Co., Inc.; Michael Nessly, Merck Research Laboratories
|
|
12:05 PM
|
A Local Influence Sensitivity Analysis for Incomplete Longitudinal Depression Data — Shuyi Shen, Eli Lilly and Company; Caroline Beucnkens, Limburgs Universitair Centrum; Craig Mallinckrodt, Eli Lilly and Company; Geert Molenberghs, Limburgs Universitair Centrum
|
| |
